United States: Capitol Hill Healthcare Update - January 10, 2017

A growing number of moderate and conservative Republicans in Congress are voicing concerns about the party's strategy to repeal the Affordable Care Act (Act) in February but then wait months – and possibly even into 2018 – before developing a replacement plan. Republicans, including President-elect Trump, have said the party's No. 1 priority is repealing the law, which they say is already in a death spiral that's causing insurance premiums to rise and coverage choices to shrink. Final repeal votes in the House and Senate are likely in mid-February. But Republicans are far from achieving internal consensus on a replacement plan, so GOP leaders want to vote quickly to repeal the ACA – with a delayed effective date of at least two years – and use the intervening time to develop a new policy.

Sens. Bob Corker (R-Tenn.), Tom Cotton (R-Ark.), Rand Paul (R-Ky.), and Bill Cassidy (R-La.), have recently voiced support for delaying the ACA repeal vote until Republicans can simultaneously unveil a replacement. Additionally, an increasing number of Republican governors in Medicaid expansion states are expressing concern about losing ACA funding, saying they will be forced to drop coverage for low-income families and individuals if the billions of dollars in federal funds are cut off. Republicans are desperate not to get tripped up politically by healthcare, but they face two competing political pressures: fulfilling a longtime campaign promise to quickly repeal the ACA, and the likely messy and lengthy process of achieving consensus on what comes next.

An acceptable middle ground according to some congressional staff could be for GOP leaders to release a set of detailed principles outlining the party's replacement plan at the same time as the ACA repeal vote. This could buy time for party leaders to work on finding policy consensus among rank-and-file lawmakers. Still, senior GOP Senate staff are confident that lawmakers will vote for a repeal-only bill despite the recent comments of GOP senators.

President-elect Trump is the wild card. So far he hasn't addressed the issue publicly. But one comment – or tweet – could upend Republicans' plans for how to navigate the hazardous policy and political shoals of ACA replacement. Trump is scheduled to talk this week with House Speaker Paul Ryan (R-Wis.), about Republicans' ACA strategy.

Democrats pressure Trump, GOP on drug prices

Saying they want to hold President-elect Trump to his campaign promises to bring down prescription drug prices, congressional Democrats introduced legislation last week that would permit the government to negotiate prices for drugs covered by Medicare Part D. Allowing Medicare to negotiate directly with drug companies – a policy long championed by Democrats – won support from Trump last year on the campaign trail. Sen. Bernie Sanders (I-Vt.) and Rep. Peter Welch (D-Vt.), introduced legislation last week that would do just that, and they called on Trump to endorse their bills.

Democrats will also push the issue with a series of amendments in the Senate this week on budget legislation that will set the stage for Republicans to advance their efforts to repeal the ACA. In addition to Sanders, Sens. Al Franken (D-Minn.), Amy Klobuchar (D-Minn.) and Sherrod Brown (D-Ohio), are expected to lead that effort, which will include an amendment authorizing drug importation. Republicans are expected to beat back the amendments, though importation has previously gained traction in the Senate and does enjoy some bipartisan support.

Democrats target HHS pick Price

One week before the Senate confirmation hearings of Rep. Tom Price (R-Ga.), begin, Democrats are stepping up criticism of the President-elect's nominee for secretary of the U.S. Department of Health and Human Services (HHS). Senate Minority Leader Chuck Schumer, (D-N.Y.), and other Democrats are calling for an ethics investigation of Price over his ownership of and trading in healthcare stocks. Democrats haven't offered evidence that Price's holdings or trades were improper, but they are demanding an outside review.

The Senate HELP Committee on January 18 will hold a hearing on Price's confirmation. Price, an orthopedic surgeon, also will be vetted next week by the Senate Finance Committee, which will be the panel that votes on advancing Price's nomination to the full Senate. Most Democrats will likely vote against the conservative Georgia congressman, who's called for the repeal of the ACA and taken other healthcare-related positions opposed by Democrats. But Democrats at the moment lack the votes to block Price from succeeding current HHS Secretary Sylvia Mathews Burwell.

Burgess to lead key House health panel

A physician will be the next chairman of a key House subcommittee that will draft ACA replacement legislation and approve new FDA-industry user fees. Rep. Michael Burgess, (R-Texas) was named last week to lead the Energy and Commerce Subcommittee on Health, which has legislative jurisdiction over the FDA and Medicare Parts B and D. First elected in 2003, Burgess has been active in healthcare policy, including the 2015 repeal of the Medicare physician reimbursement formula.

Burgess has long been critical of the ACA, and his subcommittee will play a leading role in developing legislation to replace the healthcare law. He will be active in the first six months of the year as the panel leads the effort to renew the pharmaceutical and medical device industries' user fees, which finance almost half of the FDA's budget, and to reauthorize the Children's Health Insurance Program (CHIP). Both the FDA user fees and CHIP reauthorization expire on Sept. 30.

Trump fills two key White House health posts

The staffer who will lead President-elect Trump's White House Domestic Policy Council has a long history working on healthcare policy at the HHS, the Senate and for a governor. Andrew Bremberg will become director of the council, which ensures domestic policy decisions and programs align with the president's stated goals, as well as monitors implementation of the president's domestic policy agenda.

Bremberg was chief of staff for former HHS Secretary Michael Leavitt during former President George W. Bush's administration. He previously worked for Senate Majority Leader Mitch McConnell, (R-Ky.), and Wisconsin Gov. Scott Walker. He started this summer on the Trump transition team, where he led HHS transition efforts.

Trump also announced Katy Talento will oversee healthcare policy at the council. Talento, an infectious disease epidemiologist, previously worked in the Senate, including for the HELP Committee and as a healthcare staffer for Sen. Thom Tillis (R-N.C.).

Rep. Paulsen reintroduces device tax repeal

Rep. Erik Paulsen (R-Minn.), last week introduced stand-alone legislation that would repeal the ACA's 2.3 percent excise tax on the domestic sale of medical devices. Paulsen has long opposed the device tax and has introduced legislation to repeal it in successive congressional sessions. His new legislation has 221 bipartisan House co-sponsors. The tax is currently in the second year of a two-year suspension. Without action by Congress, it is scheduled to come back into effect in 2018. It is expected that Senate Finance Committee Chair Orrin Hatch (R-Utah) will soon introduce bipartisan legislation to repeal the device tax.

The repeal of the device tax is caught up in the larger issues that surround Republican plans to repeal and replace the ACA. Some lawmakers want the ACA taxes immediately struck down, while others say the tax revenue will be needed to fund coverage while transitioning to a new healthcare plan. Another suggestion by some Republican staff would be to only suspend the device tax in an effort to keep the industry engaged in helping to propel passage of the GOP replacement plan.

Grassley expands Mylan probe

Senate Judiciary Committee Chair Chuck Grassley (R-Iowa), who has criticized the Centers for Medicare and Medicaid Services (CMS) for failing to investigate Mylan's potential overcharging of Medicaid for the EpiPen, is now questioning the agency about drugs from AstraZeneca and Purdue. In a letter last week to acting CMS Administrator Andy Slavitt, Grassley questioned whether CMS investigated the companies for misclassifying their drugs in a way that shielded them from mandated Medicaid drug rebates. Grassley said the misclassifications, which according to the senator began in 2009, have cost taxpayers "hundreds of millions of dollars" in higher Medicaid costs. He asked Slavitt for responses by January 18, just two days before President-elect Trump is sworn in.

Lawmakers object to HHS liver transplant plan

A bipartisan group of more than 70 House lawmakers is calling on HHS to change a proposal for liver transplants that they say will reduce access to transplants and increase their cost. Congress created the Organ Procurement Transplantation Network to ensure policies on organ allocation were medically based, and that patients in rural areas wouldn't be at a disadvantage compared with liver transplant patients who live closer to cities. But the lawmakers, led by Reps. Kevin Yoder (R-Kan.), and Eddie Bernice Johnson (D-Texas), say the network's plan would unfairly penalize rural communities and minority populations. The lawmakers urged HHS Secretary Burwell to withdraw the plan and solicit additional stakeholder input.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions